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Case-Based Review and Clinical Guidance on the
Use of Genomic Assays for Early-Stage Breast
Cancer: Breast Cancer Therapy Expert Group
(BCTEG)
Muaiad Kittaneh,1 Sunil Badve,2 Humberto Caldera,3 Robert Coleman,4
Matthew P. Goetz,5 Reshma Mahtani,6 Eleftherios Mamounas,7 Kevin Kalinsky,8
Elyse Lower,9 Mark Pegram,10 Michael F. Press,11 Hope S. Rugo,12
Lee Schwartzberg,13 Tiffany Traina,14 Charles Vogel15
Abstract
In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor
receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic
tests may be used to help inform treatment decisions for early breast cancer patients. Although these tests improve
our understanding of breast cancer and help to individualize treatment decisions, clinicians face challenges when
deciding on the most appropriate test to order, and the advantages, if any, of one test over another. The Breast Cancer
Therapy Expert Group (BCTEG) recently convened a roundtable meeting to discuss issues surrounding the use of
genomic testing in early breast cancer, with the goal of providing practical guidance on the use of these tests by the
community oncologist, for whom breast cancer may be only one of many tumor types they treat. The group recognizes
that genomic testing can provide important prognostic (eg, risk for recurrence), and in some cases predictive, infor-
mation (eg, benefit of chemotherapy, or extended adjuvant endocrine therapy), which can be used to help guide
treatment decisions in breast cancer. The available tests differ in the types of information they provide, and in the
patient populations and clinical trials that were conducted to validate them. We summarize the discussion of the
BCTEG on this topic, and we also consider several patient cases and clinical scenarios in which genomic testing may,
or may not, be useful to guide treatment decisions for the practicing community oncologist.
Clinical Breast Cancer, Vol. -, No. -, --- ª 2020 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The treatment of early breast cancer (EBC) is guided by well-
established clinicopathologic factors, such as tumor size, grade,
and lymph node (LN) status, as well as biomarkers such as estrogen
receptor (ER), progesterone receptor (PgR), and human epidermal
growth factor receptor 2 (HER2). These biomarkers dictate the use
of therapies such as adjuvant endocrine therapy (ET; in the case of
hormone receptor positivity), and/or antieHER2-directed therapies
such as trastuzumab, pertuzumab, trastuzumab emtansine, or ner-
atinib (in the case of HER2 overexpression/amplification).
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Clinicopathologic factors are also important to help determine the
natural history of breast cancer over time and the risk for disease
recurrence; as such, they are essential for the clinician to establish,
early in the course of disease, an overall risk assessment, which can
dictate the need for risk-reducing strategies such as adjuvant
chemotherapy.
Over the last decade, with ongoing advances in pathology, ge-
nomics, and sequencing methodologies, several commercially
available genomic tests have become available that can also help to
define the natural history of disease, and in some cases the likeli-
hood of response to specific interventions, such as adjuvant
chemotherapy. Although these tests were developed using different
methodologies and validated using different patient populations,
they have recently been incorporated (to varying degrees) into
established breast cancer treatment guidelines, including those of
the National Comprehensive Cancer Network (NCCN) and the
American Society for Clinical Oncology (ASCO). Despite this,
clinicians have unanswered questions on how to use these tests
appropriately, the utility of these tests in different patient pop-
ulations, and how to best incorporate these tests into daily use. In
addition, clinicians frequently face challenges when deciding which
test is most appropriate to use, and whether one test has any ad-
vantages over another.
About the Breast Cancer Therapy Expert Group
The Breast Cancer Therapy Expert Group (BCTEG) is a group
of expert physicians and clinical researchers who have dedicated
their careers to the treatment of patients with breast cancer. The
purpose of the group is to meet periodically to discuss important
developments related to breast cancer management, with a partic-
ular emphasis on new findings and/or areas where guidance from
established bodies, such as NCCN and ASCO, may be unresolved
or less well established. The goal is to elicit the group’s collective
opinions on a given topic as it relates to their own clinical practices,
and more importantly, how this might affect oncologists in the
community setting, who may not be as extensively versed in breast
cancer treatment. Importantly, this article is not intended to replace
any existing guidance or guidelines; nor is it an exhaustive review of
the topics in question. Rather, it is intended to present a concise
synopsis of the relevant data in the area and to summarize the
opinion of the expert group as gleaned from the meeting discussion.
Meeting Objectives and Role of Funding Sources
In previousmeetings, the group has addressed issues related to ET in
early-stage breast cancer, the use of cyclin-dependent kinase 4/6
(CDK4/6) inhibitors in patients with metastatic breast cancer, and the
treatment of HER2 positive breast cancer.1-3 In January 2019, the
group convened to discuss issues surrounding the use of genomic
testing as ameans to guide treatment decisions in EBC.An unrestricted
educational grant for this activity was provided by Agendia Inc, Bio-
Theranostics Inc, Myriad Inc, and Nanostring Inc. The faculty
members of the BCTEG were selected by Total Health Information
Services, a medical information company, based on their expert expe-
rience on this topic; theywere compensated for their participation. The
faculty and Total Health Information Services jointly selected themain
topics and general outline for the discussion. It is recognized that many
of the panelists may have relationships with corporate entities, both
related and unrelated to the topic in question; content of the discus-
sions, and any expert opinions presented herein, is intended to be based
on the panelists’ own expert clinical experience and insight, and, taking
into account current clinical practice guidelines and evidence sup-
porting them, is understood not to be influenced by any corporate
relationship or interest.
Genomic Tests
We describe some of the commercially available genomic assays
approved for use in breast cancer. Other assays are available, but the
assays listed in Table 1 were considered in the discussion because
they are the most commonly and currently used and are described in
the ASCO and NCCN guidelines.4-6 The panel also notes that at
many institutions there is a “preferred” test, and, because many tests
provide similar types of information, often key opinion leaders in
breast oncology encourage clinicians to order the test that they are
most accustomed to using. In terms of how to decide among tests,
the panel thought it was essential for the clinician to first understand
the type of information that is provided (or not provided) with each
specific test. Whereas some tests provide information that is prog-
nostic—that is, providing information about the natural history of
disease (eg, risk of recurrence within 5 years), other tests provide
information that is predictive—that is, providing information on the
likely outcome for a specific treatment or intervention (eg,
chemotherapy or extended adjuvant [EA] ET). It is also important
to recognize that certain biomarkers (eg, ER) are both prognostic
(for better outcomes) as well as predictive (for ET benefit). Another
notable example in this regard is HER2. Notably, all of these tests
can provide prognostic information on recurrence risk for years 0 to
10; 3 of the 5 tests also provide prognostic information more spe-
cifically for late recurrence—that is, years 5 to 10. Some tests are
also distinguished by their ability to provide predictive information
on either chemotherapy benefit (Oncotype DX) or EA ET benefit
(Breast Cancer Index) (Table 1). In terms of biopsy starting material
needed for genomic testing, the group recognizes that in the past,
there had been some differences in the type of tissue needed for the
different assays (eg, MammaPrint vs. Oncotype DX). Because all
assays now utilize reverse transcriptionepolymerase chain reaction
methodologies, however, formalin-fixed, paraffin-embedded sam-
ples can now be used for all assays considered in this review.
Oncotype DX (21-Gene Assay)
This test consists of 16 breast cancererelated genes (including
those involved in estrogen signaling and proliferation) as well as 5
reference genes. The assay reports a recurrence score (RS), which
ranges from 0 to 100 and initially placed patients into 1 of 3 groups:
low risk (RS ¼ 0-17), intermediate risk (RS ¼ 18-30), or high risk
(RS ¼ 31-100). The resultant score is both prognostic for distant
recurrence at 10 years and predictive for chemotherapy benefit.8,9
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-14 trial was the first validation study for the prognostic
component of the assay, and patients in the high-risk group (RS 
31) had a 30.5% rate of distant recurrence at 10 years, compared to
6.8% for those with RS < 18 (low-risk group; P < .001).8 NSABP
B-20 was the first validation study for the predictive component of
the assay; those with RS  31 had a 28% absolute benefit from
adding chemotherapy to tamoxifen (P < .001), whereas those with
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a low and intermediate (defined as RS between 18 and 30) RS did
not gain benefit from chemotherapy.9 The test was thus the first to
distinguish which node-negative, ERþ patients would benefit from
chemotherapy based on the biology of their tumor (RS  31) versus
those who were unlikely to derive benefit from chemotherapy
(RS < 18).
There remained a question, however, regarding chemotherapy
benefit in intermediate-risk patients (RS 18 to 30), which led to the
design of the TAILORx trial.10 In this trial, the intermediate range
was shifted to RS 11 to 25 in in order to minimize the potential for
undertreatment of patients, as the upper confidence limit for RS 11
represented an approximately 10% recurrence risk, which could be
considered a threshold for recommending chemotherapy. TAILORx
assigned patients to treatment based on RS, with RS 0 to 10
assigned ET alone, intermediate-risk patients (RS 11 to 25) ran-
domized to chemotherapy or no chemotherapy (all received ET),
and those with RS 26 to 100 assigned ET þ chemotherapy. Further
results from this prospective study are detailed below.
MammaPrint (70-Gene Assay)
This assay was developed from an analysis of untreated breast cancer
patients with 20-year follow-up in which 2 risk groups were compared:
a low-risk group (with no distant recurrence within 5 years) and a high-
risk group (with development of distant metastasis within 5 years).
From these studies, a 70-gene assay was developed that was prognostic
for early recurrence. Of note, ER, PgR, HER2, and the proliferation
marker Ki-67 were not among the 70 genes included in this assay.11 A
validation study was conducted in a European cohort of patients (n¼
307) diagnosed between 1980 and 1998 from the TRANSBIG
consortium with a median follow-up of 13.6 years; results showed that
the 70-gene signaturewas a strong prognostic indicator for both time to
distant metastasis and overall survival (hazard ratio ¼ 2.32 and 2.79,
respectively).12 The results of the MINDACT trial provided the cur-
rent evidence for the use of MammaPrint in both node-negative (N0)
and node-positive (Nþ) EBC.13
Breast Cancer Index
The Breast Cancer Index (BCI) integrates a prognostic 5-gene
molecular grade index and a 2-gene predictive biomarker consist-
ing of a ratio of HoxB13 and interleukin-17B receptor (H/I). The
test was initially developed as a 2-gene expression biomarker (H/I)
capable of identifying a subset of ERþ patients at risk for recurrence
in the setting of tamoxifen therapy; the molecular grade index
component of the test was subsequently shown to provide addi-
tional prognostic information.14,15 The prognostic component of
the test has been validated in approximately 1300 ERþ/LNþ pa-
tients treated with either tamoxifen or an aromatase inhibitor (AI)
across 3 study cohorts.16,17 The BCI score classifies patients as
either low (score 0-5) or high (score 5.1-10) risk for late recurrence
in years 5 through 10. In the TransATAC study, those classified as
low risk by BCI had a 3.5% rate of late distant recurrence in years 5
to 10.17 Additional data supporting the potential use of the H/I
component of BCI as a predictive biomarker for EA ET benefit are
described below.18
EndoPredict
This test offers prognostic information on 10-year risk for
recurrence for patients with ERþ/HER2 EBC. It is a 12-gene
Table 1 Commercially Available Genomic Tests in Breast Cancer and Current Guidance
Test
Type of Information
Provided Indication and Current Guidance
Key Prospective
Trials (If Available)
Oncotype DX
(21-gene assay)
 Prognostic—10-year
recurrence risk.
 ASCO: ERþ/PgRþ/HER2 node-negative disease to guide decisions on
systemic adjuvant chemotherapy.a
TAILORx
 Predictive—Adjuvant
chemotherapy benefit.
 NCCN: Best validated for its value as a prognostic
test and in predicting disease most likely to
respond to systemic chemotherapy.a
MammaPrint
(70-gene assay)
 Prognostic—10-year
recurrence risk.
 ASCO: ERþ/PgRþ/HER2 node-negative disease and HIGH
clinical risk (as per MINDACT criteria)a OR ERþ/PgRþ/HER2 node-positive
disease 1-3 positive nodes and HIGH clinical risk (as per MINDACT criteria)
to guide decisions on withholding systemic adjuvant chemotherapy.b
MINDACT
 NCCN: No recommendation.
Breast Cancer Index
(BCI)
 Prognostic—10-year
recurrence risk; late recurrence
risk (5-10 years).
 ASCO: ERþ/PgRþ/HER2 node-negative disease to guide decisions on
systemic adjuvant therapy.b
NA
 Predictive—Extended adjuvant
endocrine therapy benefit.
 NCCN: No recommendation.
EndoPredict
(12-gene assay)
 Prognostic—10-year
recurrence risk.
 ASCO: ERþ/PgRþ/HER2 node-negative disease to guide decisions on
systemic adjuvant chemotherapy.b
NA
 NCCN: No recommendation.
Prosigna
(50-gene assay)
 Prognostic—10-year
recurrence risk.
 ASCO: ERþ/PgRþ/HER2 node-negative disease to guide decisions
on systemic adjuvant therapy in conjunction with other clinicopathologic
variablesa
NA
 NCCN: No recommendation.
Unless otherwise specified, tests are not for use in node-positive, HER2þ, or triple-negative breast cancers.4-7
Abbreviations: ASCO ¼ American Society of Clinical Oncology; ER ¼ estrogen receptor; HER2 ¼ human epidermal growth factor receptor 2; NA ¼ not applicable; NCCN ¼ National Comprehensive
Cancer Network; PgR ¼ progesterone receptor.
aCurrently strong recommendation.
bCurrently moderate recommendation.
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molecular score that combines established prognostic factors such as
tumor size (T) and node status (N) to generate an individualized
score (EPclin) with a binary (low or high risk) result. The test can be
used for patients with either node-negative (N0) or node-positive
(Nþ) disease. The test was developed and validated in a popula-
tion of 964 patients with ERþ/HER2 disease who had received 5
years of tamoxifen therapy, and was subsequently validated in the
ABCSG-6, ABCSG-8, and ATAC cohorts; notably, these pop-
ulations had not received chemotherapy, received ET only, and
included both N0 and Nþ patients.19,20 Data presented at the
2018 San Antonio Breast Cancer Symposium (SABCS) showed that
among either N0 or Nþ patients, EPclin is prognostic for both early
(years 0-10) and late (years 5-15) distant recurrence. In view of the
latter result, the test may be useful to determine which patients may
be less likely to obtain benefit from EA ET.21
Prosigna (PAM50; 50-Gene Assay)
This test, also termed the PAM50 gene expression signature,
consists of 50 classifier genes and 5 control genes and is used to
define tumors into 1 of the 4 intrinsic subtypes of breast cancer:
luminal A, luminal B, HER2 enriched, and basal-like. In addition,
the test provides quantitative data on proliferation, luminal gene
expression, ESR1, PGR, and ERBB2.22,23 The test also allows for the
generation of a risk of recurrence score for postmenopausal women
with ERþ breast cancer. The test has been validated for prediction
of 10-year recurrence risk in the ATAC trial (postmenopausal
women treated with tamoxifen or AI), and in a combined analysis of
ATAC and ABCSG-8, the risk of recurrence was predictive for late
recurrence (> 5 years) for patients with hormone receptorepositive
N0 disease.24-26 Additional data are available from a Danish cohort
of patients, in whom the risk of recurrence score could identify up
to 37% of LNþ patients who could be spared chemotherapy with
good outcomes (< 5% distant recurrence at 5 years).27
Available Prospective Data:
MINDACT and TAILORx
MINDACT and TAILORx are two important trials that have
prospectively examined the value of genomic testing in EBC pa-
tients, and results from these trials have helped to shape the current
ASCO and NCCN guidance in this area.4-6 These trials are sum-
marized in Table 2. In TAILORx, the 21-gene score (Oncotype
DX) was used to define a population of patients (n ¼ 6,711,w 69%
of the total population) with an intermediate RS of 11 to 25, in
whom the benefit of chemotherapy had previously been unclear.10
The overall results of the trial showed that adjuvant ET alone and
chemo-ET were equally efficacious in this group of patients, with
similar rates of invasive disease-free survival (DFS), freedom from
distant recurrence, and overall survival. Some benefit of chemo-
therapy, however, was found in an exploratory analysis examining the
benefit of chemotherapy according to age. For example, for
patients < 50 years of age, the addition of chemotherapy improved
invasive DFS by 2.7% in the RS 16 to 20 group, and by 5.8% in the
RS 21 to 25 group. The group noted that this latter finding could be
related to the off-target effects of chemotherapy resulting in prema-
ture menopause, a notable adverse effect associated with improved
DFS.10 The group also acknowledges that findings in the under-50
age group have unfortunately added to the complexity of
interpreting results of the Oncotype DX report. Overall, however, the
TAILORx trial provides level 1 data that a sizable proportion of
EBC patients can be identified using the 21-gene assay who can be
spared adjuvant chemotherapy. A paper published after our consensus
conference further subdivided the TAILORx population based on
clinical risk (as defined by a modification of Adjuvant! Online). The
only substantive addition from this paper was to define clinically low-
risk patients with scores of 16 to 20 as not benefiting from chemo-
therapy, while clinically high-risk patients with RS 16 to 20 had
benefit similar to those with RS 21 to 25.28
It is important to note that the majority of patients (74%) ran-
domized in TAILORx were clinically low risk, and that even pa-
tients who were clinically high risk (26%) and who had a low RS, a
benefit to chemotherapy could not be identified.10 Notwithstanding
the results of TAILORx, some panelists noted that there remains a
gray zone for women with an RS of 26 to 30, as it is still unclear
exactly where the benefit of chemotherapy begins, and currently no
prospective randomized data exist for these patients. Current stan-
dard of care, however, dictates that chemotherapy should be offered
to these patients. Another noted caveat of the TAILORx trial was
that ovarian suppression was only received by approximately 13% of
patients, with 87% of the patients receiving only tamoxifen
monotherapy; in this regard, the panelists thought that the benefit
of chemotherapy in the under-50 group may be related to the
effects of chemotherapy on ovarian suppression. Indeed, such an
effect has been demonstrated to be of importance in the longer
follow-up of the SOFT/TEXT trials.29 While not recommending
any one test over another, NCCN guidelines currently recognize
the 21-gene test as best validated/preferred assay in hormone
receptorepositive/HER2/N0 patients to predict the benefit of
chemotherapy (Table 1).
Additional data are expected from the RxPONDER trial
regarding the use of this test in node-positive patients
(NCT01272037); some in the group thought that the number of
patients and events is too limited to make a clear recommendation
at this time for patients with LNþ disease and that results from
RxPONDER should be awaited. The NCCN panel, however, has
noted results from a secondary analysis of the retrospective subset
analysis of the prospective SWOG 8814 study. This analysis
showed, for patients with 1 to 3 positive LNs, no benefit of
chemotherapy in those with low RS, whereas a benefit was shown
for those with high RS  31; it also noted that the optimal cutoff to
withhold chemotherapy is unknown for patients with RS 11 to 25
at present.6,30 Some panelists also noted the results from West
German Study Group (WSG) PlanB, a prospective trial that showed
excellent 3- and 5-year DFS (98% and 94%, respectively) for pa-
tients with high clinical risk (w 62% grade 2; w 35% N1) and
RS  11.31,32 Important to note, however, are the limitations of the
WSG trial, in that the clinical consequence of omitting chemo-
therapy could only be assessed for the small group of patients with
RS < 11; indeed, a majority of patients (w 60%) had RS 12 to 25,
and the clinical benefit of chemotherapy in this group is at present
unclear.31
In MINDACT, the 70-gene signature (MammaPrint) was used
to identify a population of clinically (as defined using a modified
version of Adjuvant! Online) and genomically (as defined by
MammaPrint) discordant patients who were then randomized to
Genomic Assays for Breast Cancer
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Table 2 Summary of Available Prospective Data in Genomic Testing for TAILORx and MINDACT Trials10,13
Trial Population Studied Main Objective Key Findings Implications for Practice
TAILORx  N ¼ 10,273 women
(18-75 years) with hormone receptor
e positive/HER2/axillary N0 breast
cancer meeting NCCN criteria for
consideration of CT.
To determine whether, among patients with an
intermediate score by 21-gene assay (Oncotype DX),
ET alone is noninferior to ET þ CT.
 ET was noninferior to ET þ CT for invasive
disease-free survival at 9 years (83.3%
vs. 84.3%; HR¼ 1.08; 95% CI¼ 0.94-1.24;
P ¼ .26).
 Adjuvant CT was not beneficial for patients with
an intermediate RS of 11-25 on the
21-gene assay (Oncotype DX).
 N ¼ 6711 with
intermediate RS 11-25.
 Similar results seen for freedom from disease
recurrence at a distant site (94.5% and
95.0%) and overall survival
(93.9% and 93.8%).
 Use of the assay could identify up to
85% of early breast cancer patients who can
be safely spared CT (RS ¼ 25 or less).
 Varying degrees of CT benefit
demonstrated in women  50
years with RS of 16 to 25.
 For patients < 50, consideration should
be given to offering CT.
MINDACT  N ¼ 6693 women
(18-70 years) with primary
invasive early breast
cancer (stage T1/T2/operable
T3); 79% had N0 disease.
To determine whether women with high risk clinical
(C) features and low genomic (G) risk (C-high/G-low)
who did not receive CT had noninferior outcomes
to those who did receive CT.
 Total of 1550 patients (23.2%) had
C-high/G-low status; 5-year DMFS was
94.7% among patients in this group who did
not receive CT, meeting the criteria for
noninferiority.
 The 70-gene signature (MammaPrint) can be
useful to identify a subset of high-clinical-risk
patients with a low genomic risk (C-high/G-
low) who can safely forgo CT without impairing
outcomes.
 Clinical and genomic
risk determined by modified Adjuvant!
Online and 70-gene
assay (MammaPrint).
 Prespecified secondary analysis showed
that for patients with C-high/G-low status,
the rate of distant metastasis-free
survival was 1.5 percentage points lower than
those who did receive CT (95.9% vs.
94.4%). The result was not statistically
significant. The findings were consistent in
node-positive and node-negative patients.
Trial was not sufficiently powered to identify a
benefit to CT in this group.
 The findings represent the only prospective
data set supporting a decision to safely forgo
CT in a node-positive population.
 For C-low/G-high, patients, a benefit to
CT could not be demonstrated.
 Long-term results are pending; 10-year
follow-up analysis planned.
Abbreviations: CI ¼ confidence interval; CT ¼ chemotherapy; DMFS ¼ distant metastasis-free survival; ER ¼ estrogen receptor; ET ¼ endocrine therapy; HER2 ¼ human epidermal growth factor receptor 2; HR ¼ hazard ratio; NCCN ¼ National Comprehensive Cancer Network;
RS ¼ recurrence score.
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receive or not receive adjuvant chemotherapy based on their clinical
risk or their genomic risk. The subset of clinically high-risk (C-high)
patients who were genomically low risk (G-low) included 1550
patients (w 23% of the total population). Patients with discordant
results (ie, either C-high/G-low or C-low/G-high) were randomly
assigned to the chemotherapy group or the no-chemotherapy group
based on either the clinical result or the genomic result. The
objective was to determine whether women with high risk clinical
(C) features and low genomic (G) risk (C-high/G-low) who did not
receive chemotherapy had noninferior outcomes to those who did
receive chemotherapy. The primary objective of the study was to
show whether the lower boundary of the 95% confidence interval
for the rate of survival without distant metastasis would be at least
92%, and this primary endpoint was met, given that patients who
were C-high and G-low who did not receive adjuvant chemotherapy
(primary-test population) had a rate of survival without distant
metastasis of 94.7% (95% confidence interval, 92.5-96.2). In sec-
ondary analyses for chemotherapy benefit (not adequately powered
to detect small differences), the 5-year rate of survival without
distant metastasis was 1.5 percentage points higher for patients in
the C-high/G-low group who received adjuvant chemotherapy
versus those who did not (a finding that was not statistically sig-
nificant).13 The results thus imply that a sizable proportion of pa-
tients can be identified using MammaPrint who have good
outcomes and can safely forgo chemotherapy.
Results for the C-low/G-high group, by comparison, showed that
there was no difference in 5-year distant metastasis-free survival
when assigning treatment based on clinical risk (ie, no chemo-
therapy, 95.0%) or when assigning treatment based on genomic risk
(ie, with chemotherapy, 95.8%). The results thus imply no
advantage of assigning treatment based on genomic risk in clinically
low-risk patients. Despite the findings of MINDACT, however, it
was acknowledged that longer follow-up is needed, and a 10-year
follow-up is planned. In this regard, some panelists noted results
from the Early Breast Cancer Trialist’s Collaborative Group
(EBCTCG) on 20-year recurrence risk, showing that most of the
chemotherapy benefit occurs early in the course of disease.33
Therefore, the 5-year follow-up in MINDACT was likely suffi-
cient to identify a potential chemotherapy benefit. It should also be
noted that the Adjuvant! Online feature is currently off-line and not
available. In this regard, some in the group thought that the recent
2019 publication by Sparano et al12 might be helpful to define
cutoff points for clinical risk, referring to the so-called rule of 4 (> 3
cm þ grade 1; > 2 cm þ grade 2; > 1 cm þ grade 3).
Comparative Retrospective Data
The remaining tests—BCI, Prosigna, and EndoPredict—have
thus far not been evaluated prospectively, and data supporting their
use as a means to guide treatment decisions are limited to retro-
spective evaluations across different clinical trial populations. In
2018, Sestak et al34 published a comparison of 6 prognostic tests
across the same patient population (n ¼ 774 postmenopausal
women with ERþ/HER2 breast cancer) with long-term follow-up
data. This comparison included 2 prognostic algorithms, clinical
treatment score (CTS) and the 4-marker immunohistochemical
score (IHC4), and 4 gene expression signatures (Oncotype DX,
BCI, PAM50, and EPclin); notably, all 6 of these tests had been
previously evaluated in the same cohort of patients from the
TransATAC study.17,20,24,34,35 The results showed that all of the
signatures provided prognostic information during years 0 to 10
from women with N0 disease (n ¼ 591), whereas the prognostic
strength was weaker for the smaller number of Nþ patients with 1
to 3 positive nodes (n ¼ 183).34
With respect to late distant recurrence, however, BCI,
PAM50, and EPclin provided independent prognostic informa-
tion for both N0 patients and those with 1 to 3 positive nodes;
the authors speculated that there may be components of these
signatures that are more prognostic for recurrence in years 5 to
10, and as such could be used to provide information on the need
for EA ET to reduce recurrence risk. The study also showed that
the combination of molecular features with clinical factors (eg,
EPclin) was more informative, particularly for patients with Nþ
disease.34 Likelihood ratios were used to compare the prognostic
information provided by each test relative to the CTS; in each
case, these comparisons favored BCI, PAM50, and particularly
EPclin, all of which provided significant independent prognostic
information above the CTS for late recurrence. Some in the
group thought it was important to caution that the likelihood
ratios provided simply represent statistical comparisons among
the tests, and therefore do not provide clinical utility favoring any
one test over another.
The panelists also noted the data supporting the use of BCI as a
predictive biomarker for EA ET benefit. The predictive ability of
this biomarker was demonstrated in the MA.17 trial, which evalu-
ated the use of letrozole, an AI, in the EA setting. Specifically, for
those with a high H/I ratio, there was a significant reduction in
recurrence with EA letrozole, from 27.0% to 10.7% (P ¼ .007),
whereas for those with a low H/I ratio, there was no statistically
significant reduction in recurrence with EA letrozole therapy (P ¼
.35).18 In view of the limited absolute DFS benefit of EA therapy
with AIs (2-4.7%) and the risk for toxicity (eg, myalgias, osteopo-
rosis, and/or fracture), this test may be useful to distinguish patients
who are most likely to benefit from EA treatment with letrozole (or
another AI) versus those who will not benefit (and consequently
could be safely spared EA ET).36-38 In a further analysis of N1
patients (1-3 positive nodes), a BCI model incorporating tumor size
and grade could identify 20% of N1 patients with a low risk of
distant recurrence over 15 years (1.3%) who might be safely spared
EA ET.39 Despite these data, however, the panel notes that current
ASCO and NCCN guidelines, while supporting use of BCI as a
prognostic indicator, do not support its use as a predictive marker
for EA ET benefit.5-7 Although not discussed at the meeting, the
group also acknowledges that tools such as the Clinical Treatment
Score Poste5 Years (CTS5) are available to help inform EA therapy
decisions; recent findings have validated this clinicopathologic tool
for predicting late recurrence in a large unselected patient
population.40
Genomic Testing: Practical
Considerations
Some general clinical practice points on genomic testing in breast
cancer are summarized in Table 3. The panel suggested that the
clinician should have 3 main considerations when deciding on
genomic testing: first, whether is there a need for genomic testing at
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all; second, which of the available tests should be ordered; and third,
how the results of the test should be interpreted. In this regard, the
panel suggested that at present, genomic testing should be limited to
patients with ERþ, HER2 EBC, whereas the benefit of testing has
been less widely investigated in other patient groups, including
those with triple-negative tumors, HER2þ disease, and those with 4
or more positive LNs. Another essential concept is to recognize that
because the currently available tests were developed and validated
across different patient populations and treatment backgrounds,
they should not be considered interchangeable, and discordance
between the genomic tests is to be expected (eg, a patient having a
high risk score on one test vs. low or intermediate score on another).
To avoid this situation, which can introduce further uncertainties
and ambiguities regarding treatment, it is strongly recommended
that only one test be performed for each patient sample.
Another general point emphasized was that genomic testing
should not be ordered if the outcome of the test will not change the
course of treatment—for example, if the patient would not consider
chemotherapy under any circumstance, has commodities that
render the patient inappropriate for chemotherapy, or has clinico-
pathologic features that are clearly more informative. In other cases,
such as Nþ disease (1-3 positive nodes, where genomic testing has
been generally less well validated), it was thought that results of
genomic testing could be useful in the process of shared clinical
decision making; if considering chemotherapy, for example, the
results would be considered along with whether the patient is a valid
candidate for chemotherapy, and the patient’s overall willingness to
undergo chemotherapy. It was also recognized by the group that
there are a number of alternative scoring systems available that are
intended to either replace or supplement the use of molecular assays;
these include algorithms such as the CTS, 4-marker immunohis-
tochemical score (IHC4), and the McGee equation, which are not
included in the current ASCO or NCCN guidelines. Some of these
alternatives have shown a high rate of concordance with other
commercially available assays in assigning risk.41 Some in the group
also noted, however, that although useful, alternative assays such as
the McGee equation and IHC4 are not recommended because they
are simply looking at rate of concordance with other genomic tests,
and they have also only been tested in small numbers of patients
with few data on long-term outcomes.
Clinical Scenarios
We present below several breast cancer clinical scenarios that
might be encountered in which the need for molecular testing
might be considered. In each scenario, the group aims to answer
the questions of whether genomic testing would be appropriate for
the patient and which test might be most appropriately used,
based on the available data and clinical guidance that were in place
at the time of the January 2019 meeting. It is recognized that
more than one test might be applicable for each case, but pref-
erence was given to those assays with prospective supporting data.
The group also recognizes that other factors such as patient
preference, cost, accessibility, and coverage issues might also affect
the decision on whether to test and which assay to use, and it was
not the intent of the group to endorse any one test over another.
For cases where adjuvant chemotherapy decisions apply, Mam-
maPrint, Oncotype DX, EndoPredict, and PAM50 were consid-
ered. Although the NCCN and ASCO recognize the BCI as a
diagnostic assay having the ability to prognosticate patients who
have good outcomes without chemotherapy,4,5 most in the group
thought that the BCI would not be used in ordinary clinical
practice to guide chemotherapy decisions. Therefore, BCI was not
considered in these case scenarios. Instead, most panelists believed
that BCI should be ordered in situations where there was un-
certainty about the use of EA ET. It was also noted that, if
considering ordering BCI, it might first be determined whether
the patient will actually be compliant with the ET; for example if
a patient was known to be noncompliant with the ET in question,
then ordering the test would be less useful.
Set 1: Chemotherapy Decisions: The Clinical “High-Risk”
Patient
1A The first case scenario considered a younger patient
(40 years old) with ND disease; the patient’s tumor is
grade 2 (T2/N1), ERD, and HER2L.
Test Applicability
Type of
Evidence
Relevant
Prospective
Randomized
Study
MammaPrint Most applicable Prospective MINDACT
Oncotype DX Applicable Prospective WSG PlanB
Prosigna PAM50 Applicable Retrospective NA
EndoPredict Applicable Retrospective NA
Discussion. For this patient, the key question that genomic testing
could help inform is whether the patient should receive adjuvant
chemotherapy. In this example, the group noted that MammaPrint
Table 3 Genomic Testing in Breast Cancer: Clinical Practice Points
 Genomic testing is generally only indicated in patients with hormone receptorepositive (ERþ/PgRþ) and HER2 tumors, and those with up to 3 positive nodes.
 Genomic testing should generally not be performed for patients with hormone receptorenegative disease, > 3 positive nodes, HER2 positivity,
or TNBC outside the context of a clinical trial.
 Genomic testing should generally not be performed in patients for whom the results of the testing will not affect the course of treatment.
 Importantly, neither ASCO nor NCCN guidelines currently imply the superiority of any one genomic test over another.
 Discordance between available genomic tests is expected because the different tests were developed and validated across a range of patient
populations and treatment backgrounds; performing more than one genomic test on a patient should be avoided, as uncertainties in risk assignment may result.
Abbreviations: ASCO ¼ American Society of Clinical Oncology; ER ¼ estrogen receptor; HER2 ¼ human epidermal growth factor receptor 2; NCCN ¼ National Comprehensive Cancer Network;
PgR ¼ progesterone receptor; TNBC ¼ triple-negative breast cancer.
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would be most appropriately used, as this test can identify a sub-
group of patients that would do very well without chemotherapy,
based on the prospective data (MINDACT). Although other tests
may be applicable in this case, their use would be justified based on
limited prospective and retrospective data. Importantly, the ASCO
guidance is specific to MammaPrint for patients with 1 to 3 positive
nodes. Panelists also note here the results from the WSG PlanB trial,
which show excellent outcomes for patients with high-risk clinical
features who have RS < 11 using Oncotype DX. However, if a
more intermediate RS (eg, scores of 16-20, 21-25) was obtained,
this could lead to some confusion based on the results of TAILORx
in the under-50 age group.31,32 In addition, the small number of
patients with Nþ disease studied in both MINDACT and WSG
PlanB must be borne in mind, and as such, it would be equally
reasonable for the clinician to forego genomic testing in this patient
and proceed with chemotherapy until further prospective data are
available.
Discussion. For this clinically high-risk patient, the key question is
again which genomic test could help decide whether the patient
should receive adjuvant chemotherapy. Although the group con-
siders that prospective data are available for both MammaPrint and
Oncotype DX in this scenario, it should be noted that MammaPrint
provides only prognostic not predictive data (for chemotherapy
benefit) in this case.
Set 2: Chemotherapy Decisions: The Clinical “Low-Risk”
Patient
Discussion. The group thought that genomic profiling in general
may be less applicable for this patient, given the small tumor size,
low grade, and high hormone receptor positivity. In fact, it was
noted by some panelists that such a patient would not be tested in
Europe but would instead be treated with ET alone, as the chance
for a clinically low-risk patient having a high genomic risk is low,
and genomic testing is not considered cost-effective in this setting.
Oncotype DX would be applicable for this patient, based on pro-
spective findings from TAILORx, which included such patients.
MammaPrint is not applicable for clinical low-risk patients because
even with a high MammaPrint result (C-low/G-high), there was no
chemotherapy benefit shown in MINDACT. Prosigna PAM50 and
EndoPredict are also useful for long-term prognostication of this
patient, but their applicability would be based on retrospective
data.19,34
2B A second example considered by the group in the low-risk
category was an elderly patient (78 years old) with an 8 mm,
grade 1 tumor that is ERþ, HER2, and N0.
Discussion. In this scenario, it was agreed that based on the pa-
tient’s age and tumor size, genomic testing would not be useful.
Although some guidance (eg, NCCN) would recommend testing
based on tumor size alone (> 5 mm), other international guidance
(eg, St. Gallen) suggest that testing would not be cost-effective in
this low-risk patient.
Set 3: Endocrine Therapy Decisions
Discussion. In this scenario, genomic testing could be useful to
determine whether this high-risk patient should receive an addi-
tional 5 years of adjuvant ET with a switch to an AI. BCI was
considered most appropriately used in this scenario because it
provides both prognostic information on late recurrence risk (in this
case, after 5 years of adjuvant tamoxifen) as well as predictive in-
formation of EA ET benefit. Whereas the remaining tests can
provide useful prognostic information on late recurrence, they are
not currently utilized to determine the benefit of EA ET. Some
panelists also noted a secondary analysis of the MA.17 trial, which
demonstrated that premenopausal women (at the time of diagnosis)
who became menopausal experienced a greater than 70% reduction
1B For the second case, the group considered an older
patient (65 years old) having no comorbid conditions, with
node-negative disease. The patient’s tumor is 1.9 cm and
grade 3, ERD, HER2L, and N0.
Test Applicability
Type of
Evidence
Relevant
Prospective
Randomized
Study
Oncotype DX Most applicable Prospective TAILORx
MammaPrint Applicable Prospective MINDACT
Prosigna PAM50 Applicable Retrospective NA
EndoPredict Applicable Retrospective NA
2A The group then considered patients in the clinical low-
risk category, specifically a 65-year-old postmenopausal
woman with a pT1c (1.0 cm), N0, grade 1, ERD (99%), PgRD
(95%), HER2L, invasive ductal carcinoma.
Test Applicability
Type of
Evidence
Relevant
Prospective
Randomized
Study
Oncotype DX Applicable Prospective TAILORx
MammaPrint Less applicable Prospective MINDACT
Prosigna PAM50 Less applicable Retrospective NA
EndoPredict Less applicable Retrospective NA
3A For this scenario, the group considered a post-
menopausal woman (48 years old) who was perimeno-
pausal at the time of diagnosis; her tumor was 2 cm and
grade 3 with 1 positive node. She subsequently received
adjuvant chemotherapy and has just completed 5 years of
adjuvant tamoxifen.
Test Applicability
Type of
Evidence
Relevant
Prospective
Randomized
Study
BCI Most applicable Retrospective NA
MammaPrint Applicable Retrospective MINDACT
Oncotype DX Applicable Retrospective TAILORx
Prosigna PAM50 Applicable Retrospective NA
EndoPredict Applicable Retrospective NA
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in recurrence with the addition of letrozole; the role of BCI in this
subgroup of patients remains unclear.
Discussion. For this patient, the concern once again is whether to
extend ET for this lower-risk patient, and it would be desirable to
determine the patient’s late recurrence risk (years 5-10) as well as
her likelihood of response to ET. Whereas all of the assays can
provide information on years 0 to 10 recurrence risk, based on
retrospective analyses, BCI, PAM50, and EPclin are more prog-
nostic for late recurrence (years 5-10).34 Because BCI is also pre-
dictive for EA ET benefit in the MA.17 trial, it is most applicable in
this case.17
Conclusions
Genomic assays in breast cancer provide an additional tool for the
clinician to help refine treatment decisions, including the use of
adjuvant chemotherapy or EA ET; these tests should be used to
assist in shared decision making between the patient and oncologist.
When deciding whether to test a patient, clinicians should consider
the overall need for the test, which test is most appropriate, and how
the expected results of the testing should be interpreted. It is also
important for oncologists to understand and differentiate among the
available genomic tests by the type of information provided (prog-
nostic or predictive), bearing in mind that some tests provide both
types of information. Some panelists also thought that the most
useful tests are those that provide both prognostic information (eg,
10-year recurrence risk) as well as predictive information (eg, the
benefit of chemotherapy). Other panelists, however, thought that
even determination of overall prognosis alone was useful for them
when making treatment decisions.
The panelists cited several examples of patients for whom
genomic testing would not be indicated—for example, an older
patient with a grade 1 subcentimeter tumor, or a patient with 3 or
more positive nodes. There was general consensus that genomic
testing should not be done for patients in whom the outcome will
not change the course of treatment—for example, if the clinician
already knows the patient is not suitable to receive chemotherapy
(eg, due to age, comorbid conditions) or would decline chemo-
therapy. Although some tests (eg, Oncotype DX, MammaPrint) had
been more widely used by the panelists and have the added value of
prospective data to support their indications, the panel agreed there
is currently insufficient evidence to recommend any one test over
another, and ASCO and NCCN guidelines are reflective of this.
Last, although not discussed formally at the meeting, the group
notes that overall data on the benefit/clinical utility of genomic
testing are at present limited in several settings, such as younger
women (< 30 years of age), male breast cancer patients, the
neoadjuvant setting, and patients with positive LNs. Forthcoming
results from trials such as RxPONDER and OPTIMA should help
assess the benefit of genomic testing in relation to receipt or
nonreceipt of chemotherapy, particularly for patients with Nþ
disease (Table 4). In RxPONDER (NCT01272037), patients will
have ERþ/HER2 disease with 1 to 3 positive nodes and an RS
of 25 or less.42 In OPTIMA, patients will have ERþ/HER2
disease with 1 to 9 positive nodes, or N0 disease with tumor size
Table 4 Genomic Testing in HRD/HER2L Node-Positive Breast Cancer in RxPONDER and OPTIMA Trials
Study Study Population Study Description and Primary Endpoint Timeline
RxPONDER
[NCTNCT01272037]
 HRþ/HER2 disease.  Phase 3 study of standard adjuvant ET (tamoxifen or AIs)
with or without chemotherapy.
Forthcoming; primary completion
estimated for 2022.
 1 to 3 positive nodes.  Cox regression will be used to examine the interaction of linear
RS with chemotherapy benefit; goal will be to define a cut point
for recommending chemotherapy for patients with RS 0 to 25.
 Oncotype DX (21-gene assay)
RS of 25 or less.
OPTIMA [research.uk]  HRþ/HER2 disease.  Phase 3 study examining the impact of chemotherapy
with 5 to 10 years’ ET in patients with HRþ/HER2
node-positive disease.
Forthcoming; trial is currently
recruiting until 2021.
 Age  40 years.  Group 1 will receive chemo-ET without testing
 Chemotherapy eligible.  In group 2, Prosigna (50-gene assay) will be used to stratify
patients to chemo-ET or ET alone.
 Up to 9 LNs positivea; or LN0
with  30 mm tumor.
Abbreviations: AI ¼ aromatase inhibitor; ET ¼ endocrine therapy; HER2 ¼ human epidermal growth factor receptor 2; HR ¼ hormone receptor; LN ¼ lymph node; RS ¼ recurrence score.
aIf only 1 to 3 nodes positive, spread across > 2 mm across in at least 1 node; or if tumor > 20 mm spread to 1 to 3 nodes and < 2 mm across in each node.
3B Decisions regarding EA ET may also apply to low-risk
patients; for this example, the group considers a 64-year-
old patient with a grade 2 tumor that is node negative (T2/
N0) ERD (80%), PgRD (70%), and HER2L. The patient
received adjuvant tamoxifen for 5 years but is concerned
about extending adjuvant therapy with an AI for fear of
adverse events and concern about having a late recurrence.
Test Applicability
Type of
Evidence
Relevant
Prospective
Randomized
Study
BCI Most applicable Retrospective MA.17
MammaPrint Applicable Retrospective NA
Oncotype DX Applicable Retrospective NA
Prosigna PAM50 Applicable Retrospective NA
EndoPredict Applicable Retrospective NA
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> 30 mm.43 Additional data are also needed with longer-term
outcomes in patients who have high-risk clinical features but
whose genomic risk is scored low and who might be spared
chemotherapy.
Note Added in Proof
After this meeting, an update to the ASCO 2016 guidance was
published that incorporated results from TAILORx (Andre F, et al.
J Oncol Pract 2019, JOP1900264; Andre F, et al. J Clin Oncol
2019; 37: 1956-64). In the setting of patients with ERþ/HER2/
N0 disease, strong recommendations were made to consider ET
alone for (1) patients  50 years with RS < 26, and (2) patients 
50 years with RS < 16, and also to consider chemo-ET for all
patients with RS > 30. Moderate recommendations were made to
consider chemo-ET for patients  50 years with RS 16 to 25, and
in all those with RS 26 to 30. Further guidance from ASCO
regarding use of the 21-gene assay in node-positive disease is also
expected soon.
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